Skip to Main content Skip to Navigation
Journal articles

Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?

Abstract : Omalizumab is a recombinant humanized monoclonal antibody (mAb) targeting IgE, produced using Chinese hamster ovary (CHO) cell culture. It has been approved for the treatment of severe allergic asthma (SAA) and chronic urticaria but not for allergic rhinitis (AR), atopic dermatitis (AD) or food allergy, despite some benefits against these diseases [1]. Omalizumab treatment associated with allergen immunotherapy (AIT) can increase the tolerability of AIT [1]. Some anaphylactic reactions have been [...]
Complete list of metadata

https://hal-pasteur.archives-ouvertes.fr/pasteur-03718435
Contributor : Pascal Poncet Connect in order to contact the contributor
Submitted on : Friday, July 8, 2022 - 5:35:22 PM
Last modification on : Thursday, August 4, 2022 - 5:28:01 PM

Identifiers

Citation

Angelica Tiotiu, Claire Poreaux, Pascal Poncet, Hélène Senechal, J.L. Schmutz. Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?. European Journal of Dermatology , 2019, 29 (1), pp.101-2. ⟨10.1684/ejd.2018.3454⟩. ⟨pasteur-03718435⟩

Share

Metrics

Record views

0